More Research Needed for Vitamin D's Cardiac Effect in PCI

This article originally appeared here.
Share this content:
More Research Needed for Vitamin D's Cardiac Effect in PCI
More Research Needed for Vitamin D's Cardiac Effect in PCI

TUESDAY, Sept. 5, 2017 (HealthDay News) -- More research is needed to assess the role of vitamin D in the prevention of periprocedural myocardial injury, according to a study published online Aug. 25 in the Journal of Clinical Pharmacology.

Naser Aslanabadi, M.D., from Tabriz University of Medical Sciences in Iran, and colleagues randomized 99 patients admitted for elective percutaneous coronary intervention (PCI) into vitamin D (52 patients) and control (47 patients) groups. Twelve hours before PCI, the intervention group received 300,000 IU vitamin D orally.

The researchers found that 42 percent of patients in the control group and 34.6 percent in the intervention group had an increase in creatine kinase-MB (CK-MB) (P = 0.417). The increase in cardiac troponin I occurred in 8 percent of patients in the control group and 3.3 percent in the intervention group (P = 0419). There were no significant changes in the level of cardiac biomarkers. The mean difference in CK-MB between eight and 24 hours was significantly lower in the vitamin D group (P = 0.048). The vitamin D group also had significantly lower mean difference in high-sensitivity C-reactive protein (P = 0.045).

"This study could not show a clear effect of vitamin D in the prevention of cardiac injury during elective PCI," the authors write. "Based on the results of the present study, larger outcome-based, double-blind, placebo-controlled trials with a longer duration of vitamin D administration to correct the level of vitamin D above 30 ng/mL are recommended to demonstrate a clear effect of vitamin D supplementation in the prevention of cardiac injury following elective PCI."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »